COPD pharmacogenetics studies must consider these disease-susceptibility and disease-modifying genes, in addition to genes involved in drug absorption, distribution, metabolism and excretion ...

Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...

Patients with COPD and established cardiovascular disease have more MACEs and seek less preventive cardiac care than patients with CVD alone.

Asthma and chronic obstructive pulmonary disease (COPD) are chronic respiratory (lung) diseases that cause breathing difficulty and coughing. Asthma affects about 28 million people in the United ...

Climate change is affecting the health of all individuals and represents an even more significant health risk for individuals with COPD.

E-cigarette use is linked to increased risk of COPD and possibly hypertension, though less harmful than traditional smoking, ...

Ottawa, April 08, 2025 (GLOBE NEWSWIRE) -- The global chronic obstructive pulmonary disease market size was valued at USD 22.55 billion in 2024 and is predicted to hit around USD 33.29 billion by ...

A new study from University Hospitals Connor Whole Health found that it was feasible to conduct a hybrid music therapy ...

chronic obstructive pulmonary disease (COPD), and ... How a New Gut Microbe Drives the Gut-Lung Axis Dec. 19, 2024 — A team has discovered a new communication pathway between the gut and lung.

Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden ...

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria ...